Atara Biotherapeutics, Inc.

158 articles with Atara Biotherapeutics, Inc.

• Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

  8/2/2021

  Atara Biotherapeutics, Inc. today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021

  8/2/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 110,626 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 69,744 shares of Atara’s common stock to 8 such newly hired employees.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 02, 2021

  7/2/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired employees and stock options to purchase an aggregate of 99,585 shares of Atara’s common stock to 12 such newly hired employees.

• Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers

  7/1/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the Company has joined the Rare Disease Company Coalition.

• Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

  6/7/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 04, 2021

  6/4/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 140,861 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 124,966 shares of Atara’s common stock to 7 such newly hired employees.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 14, 2021

  5/14/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of inducement awards to Cokey Nguyen, its Senior Vice President, Chief Scientific Officer.

• 

  BioSpace Movers & Shakers, May 14

  5/14/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.

• Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit

  5/13/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Cowen Virtual Oncology Innovation Summit

• Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

  5/10/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Cokey Nguyen, Ph.D. as Chief Scientific Officer.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 07, 2021

  5/7/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock to 47 newly hired employees and stock options to purchase an aggregate of 206,167 shares of Atara’s common stock to 15 such newly hired employees.

• Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

  5/4/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business highlights and key catalysts over the next 18 months.

• Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

  4/27/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financial results after market close on Tuesday, May 4, 2021

• 

  BioSpace Movers & Shakers, April 9

  4/9/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Apr 02, 2021 - Apr 02, 2021

  4/2/2021

  Atara Biotherapeutics, Inc. reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock to 24 newly hired employees and stock options to purchase an aggregate of 82,342 shares of Atara’s common stock to five such newly hired employees.

• Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting

  3/14/2021

  Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR)

• Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

  3/9/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will participate in a fireside chat at the Virtual 33rd Annual ROTH Conference

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Mar 05, 2021

  3/5/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired employees and stock options to purchase an aggregate of 55,000 shares of common stock to four such newly hired employees.

• Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

  2/18/2021

  Live Conference Call and Webcast at 4:30 p.m. EST

• Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

  2/8/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the presentation of data supporting the proposed mechanism of action of their lead product candidate, tabelecleucel (tab-cel®), and five additional poster presentations at the Transplantation & Cellular Therapy (TCT) Meeting